Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy

INTRODUCTION: Targeted therapies for aggressive breast cancers like triple negative breast cancer (TNBC) are needed. The use of small interfering RNAs (siRNAs) to disable expression of survival genes provides a tool for killing these cancer cells. Cyclin dependent kinase 11 (CDK11) is a survival pro...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Kren, Betsy T, Unger, Gretchen M, Abedin, Md J, Vogel, Rachel I, Henzler, Christine M, Ahmed, Khalil, Trembley, Janeen H
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4344788/
https://ncbi.nlm.nih.gov/pubmed/25837326
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-015-0524-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados